Non-small cell lung cancers, particularly squamous cell carcinoma and adenocarcinoma subtypes, have long posed a staggering challenge for oncologists. While immunotherapy has revolutionized treatment paradigms in recent years, a substantial fraction of patients either fails to respond or eventually develops resistance, underscoring the urgent need for novel approaches. The OSUCCC – James team focused their investigation on the lysosome, a cellular organelle integral to maintaining cellular equilibrium through nutrient recycling and metabolic regulation, and a protein known as SREBP-1, a master regulator of lipid and glucose metabolism within tumor cells.

Previous attempts to suppress tumor growth through lysosomal inhibition — employing drugs such as chloroquine (CQ) — have yielded only modest success. Such therapies aim to disrupt the tumor’s metabolic adaptability by impairing lysosome activity, thereby limiting nutrient access necessary for unchecked proliferation. However, tumors have consistently demonstrated an uncanny ability to circumvent such interventions, maintaining metabolic fluxes and promoting survival despite therapeutic pressure. This study provides the first evidence that tumor cells activate a compensatory glucose-lipid metabolic feedback loop mediated by SREBP-1, effectively blunting the impact of lysosomal inhibitors.

At the heart of the discovery is a complex signaling cascade wherein SREBP-1 not only enhances glucose uptake but also orchestrates lipid biosynthesis pathways that cooperate to sustain tumor growth. By increasing glucose flux into the cancer cells, SREBP-1 counterbalances the metabolic disruption caused by lysosomal inhibition, facilitating mitochondrial resilience, and reducing oxidative stress-induced apoptosis. This metabolic plasticity confers a survival advantage, rendering single-agent lysosomal inhibitors insufficient.

The researchers employed sophisticated preclinical models involving both cell cultures and animal subjects to unravel this mechanism. They demonstrated that combining lysosomal inhibitors with agents that simultaneously disrupt glucose transport can induce mitochondrial dysfunction, heighten oxidative stress, and trigger extensive tumor cell death. This dual targeting strategy effectively dismantles the metabolic safety net tumors rely on in the face of lysosomal suppression.

“Our findings reveal an unanticipated metabolic crosstalk and regulatory loop that tumors exploit to withstand lysosomal-targeted therapy,” explained Deliang Guo, PhD, founding director of the Center for Cancer Metabolism at OSUCCC – James and corresponding author of the study. “By intervening at multiple metabolic nodes, particularly glucose and lipid metabolism along with lysosomal activity, we can strategically dismantle tumor defenses and enhance therapeutic efficacy.”

This metabolic feedback loop is significant not just for lung cancers but potentially for a broad spectrum of malignancies characterized by elevated metabolic demands. Tumors with aggressive phenotypes often exhibit heightened uptake of glucose and lipids, which fuels their rapid growth and resistance to stress. Targeting the metabolic flexibility of tumors thus emerges as an innovative avenue to overcome resistance mechanisms that have stymied conventional therapies.

Yaogang Zhong, PhD, senior author and lead researcher on the project, emphasized the clinical relevance: “This approach holds particular promise for patients with lung squamous cell carcinoma and specific subsets of adenocarcinoma who lack actionable genetic mutations, leaving them with limited treatment options. The combinatorial therapeutic strategy we propose harnesses existing drugs with well-established safety profiles, expediting the bench-to-bedside transition.”

Indeed, both chloroquine and simvastatin — commonly used in clinical settings for malaria and cholesterol management respectively — are repurposed drugs that the study utilized. Furthermore, the fatty acid synthesis inhibitor TVB-2640, already in advanced phase II/III clinical trials, complements this triple-pronged assault on tumor metabolic machinery. The convergence of these agents into a cohesive treatment protocol highlights the translational potential of the findings.

Mechanistically, glucose transporter inhibition amplifies mitochondrial vulnerability by preventing the energy substrate influx required for survival during lysosomal stress. This mitochondrial damage precipitates oxidative stress, destabilizing tumor cell homeostasis and culminating in apoptosis. Simultaneously, lipid metabolism disruption interrupts membrane biogenesis and signaling lipid production essential for tumor viability, collapsing the compensatory metabolic loop.

This research not only deepens fundamental understanding of cancer metabolism but also advocates for integrated therapeutic regimens that consider the networked nature of tumor survival pathways. By exploiting the metabolic dependencies of tumors, combinations that target lysosomal pathways in concert with glucose and lipid metabolic circuits can yield robust antitumor responses.

As the metabolic landscape of cancer cells continues to be an ever-expanding frontier, these findings illuminate new targets and strategies to counteract the adaptability that makes tumors so formidable. The study thus marks a pivotal advance in precision oncology, setting the stage for clinical trials that could redefine treatment standards for patients with refractory lung cancers.

Future investigations are poised to explore the applicability of this metabolic combination approach to other cancer types exhibiting metabolic plasticity. Moreover, understanding the precise molecular interactions within the glucose-lipid-lysosome axis may uncover additional therapeutic targets and biomarkers predictive of treatment response.

In conclusion, this seminal study spearheaded at OSUCCC – James offers a compelling roadmap to outmaneuver NSCLC resistance by dismantling a metabolic feedback loop critical for tumor persistence. Through strategic combination therapies that are already clinically accessible, there is renewed hope to significantly improve outcomes for patients battling some of the most aggressive and treatment-resistant lung cancers.

Subject of Research: Tumor resistance mechanisms in non-small cell lung cancer; lysosomal inhibition and metabolic regulation.

Article Title: SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibition

News Publication Date: 28-Jan-2026

Web References:
https://cancer.osu.edu
https://pubmed.ncbi.nlm.nih.gov/41604461/

Image Credits: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Keywords: Non-small cell lung cancer, lysosomal inhibition, SREBP-1, glucose metabolism, lipid metabolism, tumor resistance, chloroquine, simvastatin, TVB-2640, metabolic therapy, cancer metabolism, therapeutic strategy

Cancer cells are notorious for their voracious appetite for glucose, deviating sharply from normal cells by metabolizing glucose in a manner that yields far less energy per molecule. This metabolic quirk, first noted by Otto Warburg in the early 20th century, has perplexed scientists for decades. Why would rapidly proliferating cells adopt a less efficient energy-generation pathway like aerobic glycolysis, when oxidative phosphorylation — the process that yields far more ATP — remains available? The answer has remained one of cancer biology’s most compelling mysteries, demanding sophisticated investigative approaches to untangle.

The research team approached this quandary by integrating stable isotope tracing with ^13C-metabolic flux analysis and flux balance analysis—a computational technique that models the flow of metabolites through complex biochemical networks. By tracing the fate of ^13C-labeled glucose fed into cancer cells, they meticulously mapped metabolic pathways, quantifying how glucose metabolites traverse the cellular network. This data was then synthesized through a flux balance model to simulate metabolic flow, offering an unprecedentedly precise portrait of cancer metabolism in silico.

Their findings reveal a compelling thermodynamic rationale for the Warburg effect. Contrary to conventional wisdom that inefficient metabolism is merely a byproduct of malignancy, the study shows that aerobic glycolysis reduces metabolic heat output compared to oxidative phosphorylation. This reduction in metabolic thermogenesis may confer a survival advantage to cancer cells by mitigating detrimental heat accumulation, optimizing energy use within the tumor microenvironment, and potentially influencing cellular signaling pathways sensitive to thermal fluctuations.

The study meticulously demonstrates that cancer cells’ reliance on glycolysis is not a simple deficit but a carefully balanced metabolic adaptation. By siphoning energy through aerobic glycolysis, cancer cells may juggle energy production with the biosynthetic demands required for rapid proliferation. The flux analysis underscores that this metabolic redirection enables cancer cells to divert crucial glycolytic intermediates toward anabolic processes such as nucleotide, amino acid, and lipid synthesis—foundations for building new biomass—while keeping heat production in check.

Harnessing this integrative methodology, the researchers not only dissect the biochemical logic underpinning the Warburg effect but also provide a computational framework that can predict cancer-specific metabolic states. This tool can simulate how alterations in gene expression, enzyme activity, or nutrient availability may ripple through metabolic networks, affecting cancer cell survival and growth. Such predictive modeling is invaluable for designing therapeutic interventions that exploit metabolic vulnerabilities unique to cancer cells.

The interdisciplinary nature of this work, merging experimental biochemistry, systems biology, and information science, underscores the complexity of deciphering cancer metabolism. Lead author Dr. Nobuyuki Okahashi emphasizes that coupling metabolic flux analyses with computational simulations can unravel multilayered metabolic rewiring far more effectively than either approach alone. This integrated strategy reveals latent patterns and regulatory mechanisms that remain invisible using traditional experimental paradigms.

Importantly, the thermodynamic perspective introduced by this study challenges prevailing dogma and invites reconsideration of metabolic inefficiency in cancer as a strategic phenotype rather than a mere hallmark of dysfunction. By reducing heat generation, cancer cells might evade stress-induced damage and modulate their microenvironment to favor growth and immune evasion. These insights reposition metabolic thermogenesis as a critical factor in tumor biology and potentially, treatment resistance.

The implications for cancer therapy are profound. Targeting metabolic recalibrations that confer reduced thermogenesis and enhanced biosynthetic capacity could disrupt cancer cell homeostasis. Therapeutic agents designed to rebalance metabolic flux toward more energy-efficient but heat-generating pathways might sensitize tumors to heat stress or impair their biosynthetic machinery. This represents a paradigm shift where metabolic heat production and intracellular thermoregulation become therapeutic targets, alongside canonical oncogenic pathways.

Moreover, the study’s approach offers a blueprint for personalized medicine. Using patient-derived data to populate flux balance models could identify individual metabolic dependencies, guiding the selection of metabolic inhibitors tailored to disrupt specific tumor metabolic states. Such precision therapies would minimize off-target effects, sparing normal tissues while exploiting cancer-specific vulnerabilities illuminated by flux analyses.

The collaborative effort between Osaka and Kanazawa Universities exemplifies the power of interdisciplinary research in confronting the multifaceted challenges of cancer biology. By bridging biology, engineering, and computational science, these investigators have provided a robust platform for both fundamental discovery and translational application. Their work heralds a new era where metabolism-centric views drive innovation in cancer diagnosis, prognosis, and therapy.

This research underscores the vital importance of quantifying cellular metabolism with unprecedented granularity. As cancer metabolism continues to be recognized as a cornerstone of malignancy, integrating experimental isotopic tracing with computational systems biology will be critical to unlocking how aberrant metabolic states support tumor progression and resistance. The knowledge gleaned here lays groundwork that future studies will expand to encompass diverse cancer types and microenvironmental contexts.

In conclusion, the elucidation of cancer cells’ metabolic heat regulation coupled with their glycolytic predilection provides a fresh lens through which to view tumor biology. This study’s synthesis of metabolic flux analysis and computational modeling not only clarifies a longstanding cancer paradox but also opens promising therapeutic vistas. By understanding and ultimately manipulating cancer metabolism’s thermodynamic balance, we edge closer to more effective, less toxic cancer treatments that exploit the unique physiologic quirks of cancer cells themselves.

Subject of Research: Cells

Article Title: Metabolic flux and flux balance analyses indicate the relevance of metabolic thermogenesis and aerobic glycolysis in cancer cells

News Publication Date: 20-Aug-2025

References: DOI: 10.1016/j.ymben.2025.08.002

Image Credits: Nobuyuki Okahashi

Keywords: Life sciences; Diseases and disorders; Cancer; Cancer metabolomics; Biotechnology; Information technology; Drug discovery